Pro generics
The Pro Generika e. V. is the interest group of generic and biosimilar companies in Germany. He represents 15 companies (as of May 2017). According to their own statements, generics companies cover 77 percent of the total demand for drugs of the statutory health insurance .
The seat of the association is Berlin. There he mainly represents interests on questions of sustainable drug supply with generics and biosimilars and their legislative and economic framework. Wolfgang Späth (Hexal AG) has been the chairman of the association's board of directors since June 21, 2007.
The pro-generics code of conduct, which applies equally to all members, is intended to guarantee ethically sound cooperation with members of the medical specialist community such as doctors, health care institutions and patients.
aims
The association is committed to a strong generics and biosimilar location in Germany. Legislation with little bureaucracy for the markets for generics and biosimilars is imperative from the point of view of the association in order to achieve this goal. Only thus arises a competition that ultimately affordable care for patients with drugs guarantee. Fair competition and drug discount agreements are central themes in the work of the association.
Association structure
The share of member companies in the generics market in 2016 was 69 percent in terms of sales and 55 percent in terms of sales (source: IMS Phamascope). With regard to the entire pharmaceutical market of statutory health insurance, the members of Pro Generika had a market share of 50 percent in 2016 based on sales and 14 percent based on sales (source: INSIGHT Health NVI-KT).
history
ratiopharm GmbH , AbZ-Pharma GmbH , CT Arzneimittel GmbH, ribosepharm GmbH, STADA pharm GmbH, ALIUD PHARMA GmbH & Co. KG were among the founding members of the association in 2004.
As of May 2017, the association has 15 members.
These are: 1A Pharma GmbH, AbZ-Pharma GmbH , ALIUD PHARMA GmbH & Co. KG, Aristo Pharma GmbH, Basics GmbH - A SUN PHARMA company, Fresenius Kabi Deutschland GmbH, Hexal AG , Mylan dura GmbH, Mylan Healthcare GmbH, OmniVision GmbH , PUREN Pharma GmbH & Co. KG, ratiopharm GmbH , STADA pharm GmbH, TEVA GmbH, ZENTIVA Pharma GmbH
Extraordinary members are: ifap Service Institute for Doctors and Pharmacists GmbH, IMS HEALTH GmbH & Co. OHG, INSIGHT Health GmbH & Co. KG, intermedix Deutschland GmbH
Working groups
The Pro Biosimilars working group has been active under the umbrella of the association since May 2015. The AG is open to all companies that develop, manufacture or market biosimilars in Germany.
It advocates needs-based access for patients to modern biopharmaceutical drugs, affordable care and fair and sustainable competitive conditions.
Controversy
In a contribution on the satirical program heute-show in May 2010 about overpriced drugs, the satirist Martin Sonneborn conducted an interview with the then managing director Peter Schmidt. When asked whether we must assume that we will be supplied with “cheap Chinese tablets” in the near future, the pharmaceutical lobbyist replied, among other things, that free drugs “could be easily copied” and “many products [...] are relatively easy to manufacture”. In addition, cheap drugs such. B. from China "not necessarily worse". For the most part, statements by Schmidt were broadcast that were not intended for the public and had been made during the interviews, for example. Schmidt was annoyed about the broadcast and described it as a “real mess”, because Sonneborn had lured him with the request for a ZDF interview, which is “if possible in one of the 'heute' programs, preferably in ' heute-journal ', place “wool. Sonneborn himself spoke of a misunderstanding. After Peter Schmidt became managing director of Pro Generika e. V. had been dismissed, reprimanded Thomas Bellut , then program director of the ZDF, this procedure and forbade the editorial staff of the heute-show to work with the brands heute und heute-journal .
Web links
Individual evidence
- ↑ http://www.progenerika.de/verband/trägers-unternehmen/
- ↑ http://www.progenerika.de/verband/grundsaetze-zielstellung/
- ↑ Executive Board and Office - Pro Generika eV In: Pro Generika eV ( progenerika.de [accessed on April 12, 2017]).
- ↑ http://www.progenerika.de/wp-content/uploads/2016/09/Pro-Generika-Ver heskodex- final_6.9.2016.pdf
- ↑ https://www.deutsche-apotheker-zeitung.de/news/artikel/2016/12/05/pro-generika-warnt-vor-engpaessen-durch-zyto-rabattvertraege
- ^ Pro Generika eV: 1 statement from Pro Generika on the “Draft of a law to strengthen the supply of pharmaceuticals in the GKV” (BT-Drucksache 18/10208). (No longer available online.) November 22, 2016, formerly in the original ; accessed on April 12, 2017 (German). ( Page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.
- ^ The member companies of Pro Generika eV In: Pro Generika eV ( progenerika.de [accessed on April 12, 2017]).
- ^ Pro Biosimilars - Pro Biosimilars Working Group. Retrieved April 12, 2017 .
- ↑ Doctors newspaper: Biosimilars: Pro Generika sees opportunities unused. Retrieved April 12, 2017 .
- ↑ Doctors newspaper: Pro Generika: Pharmaverband demands opening of the biopharmaceutical market. Retrieved April 12, 2017 .
- ↑ a b Oliver Welke , Morten Kühne : heute-show. The book . Berlin 2011, p. 219 f. ISBN 978-3-87134-699-6 .
- ↑ Dismissed pro generics boss Peter Schmidt. heilpraxisnet.de, June 12, 2010, accessed on December 27, 2011 .
- ↑ Because of tricks during an interview - ZDF program director reprimands "heute-show". spiegel.de, May 21, 2010, accessed on November 27, 2010 .
